E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study.

ABSTRACT:

Background

E7386 is an orally active inhibitor reported to block the CBP/β-catenin interaction. We present data from the dose-escalation and expansion part 1 of Study 103 (phase I) of E7386 in patients with advanced, unresectable, or recurrent (A/U/R) solid tumors.

Patients and methods

This open-label study was conducted in Japan. In dose-escalation, eligible patients aged ≥20 years were diagnosed with A/U/R solid tumors with no alternative standard/effective therapies. In the expansion part, eligible patients were diagnosed with A/U/R colorectal cancer (two or more prior systemic anticancer therapies) or other gastrointestinal tumors (one or more prior systemic anticancer therapy). The primary objective was assessment of safety and tolerability. Secondary objectives were as

SUBMITTER: Kondo S 

PROVIDER: S-EPMC12800764 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature